UNSPSC 51332810: Cyamemazine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H21N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A2JGV5CNU4, chemically known as 10h-phenothiazine-2-carbonitrile, 10-(3-(dimethylamino)-2-methylpropyl)- (9ci) but generally known as cyamemazine, which bears US NIH Compound Identifier 62865. European Medicines Agency schedules Cyamemazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06836MIG.

UNSPSC 51332810 Cyamemazine, a Commodity code, shows minimal alignment between its nominal scope and actual state and local procurement activity. The three recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and multi-source generic pharmaceuticals — none of which are cyamemazine, an antipsychotic pharmaceutical. State and local governments tagging these solicitations with the 51332810 code appear to be using it as a catch-all for pharmaceutical products rather than as a discrete identifier for cyamemazine specifically. The work being procured spans community health naloxone distribution, pharmacy benefit program modernization, and cooperative multi-state generic drug contracting, suggesting the code's current use encompasses a much broader range of pharmaceutical goods and services than its name indicates.

Recent opportunities appear in Florida (Seminole County's naloxone and drug deactivation systems IFB, due July 26, 2023), Texas (Texas Health and Human Services Commission's RFI for direct-to-manufacturer prescription programs, due April 3, 2026), and Minnesota (MMCAP's multi-state generic pharmaceuticals RFP, due March 26, 2026, with participating states including Oregon). Issuing bodies range from county health agencies to state health and human services departments and multi-state cooperative purchasing alliances. Because the code's label does not match the actual commodity being solicited in any of the three opportunities, business development professionals should treat 51332810 as an unreliable code marker and rely instead on direct solicitation search by product name, therapeutic category, or cooperative vehicle when targeting state and local pharmaceutical procurement.